en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


3/2009
vol. 47
 
Share:
Share:
abstract:
Short communication

Standards of treatment
of the National Consultant for Rheumatology standpoint for the biologic therapy of juvenile idiopathic arthritis

Lidia Rutkowska-Sak
,
Ewa Tuszkiewicz-Misztal
,
Henryka Brózik
,
Marek Niedziela
,
Zbigniew Żuber
,
Witold Tłustochowicz
,
Piotr Wiland

Reumatologia 2009; 47, 3: 111–115
Online publish date: 2009/08/11
View full text Get citation
 
Juvenile idiopathic arthritis (JIA) is the most common chronic autoimmune disease in children. Treatment relies mostly on nonsteroidal anti-inflammatory drugs, corticosteroids, and disease – modyfying antirheumatic drugs. “Biologics” (anticytokine drugs) are an important therapeutic option for treating patients with JIA and will be introduced as therapy in the course of patients, who inadequately respond to conventional disease-modyfying antirheumatic drugs, preferred methotrexate. In the publication we present the position of the expert pediatric rheumatologist panel of the National Consultant for Rheumatology concerning anticytokine drugs in JIA treatment.
keywords:

juvenile idiopathic arthritis, therapy, anticytokine drugs




Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.